Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

News Conference News TCT 2016

Are Full, Formal Guidelines Still Useful in the Rapidly Changing TAVR Field?

Todd Neale

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Early Insights from Industry

Presenter: Charles J. Davidson, Nicole Ibrahim, Dan Mans

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Charles J. Davidson, Nicole Ibrahim, John C Laschinger

October 30, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation TCT 2015

Cangrelor IV: Transitioning to Oral ADP Antagonists

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

News Conference News TCT 2015

Keynote: Simplified Trials, Community Engagement Key to Reinvention of Clinical Research

October 13, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

Presentation TCT 2014

Bendavia to Prevent Mitochondrial Transition Pore Opening

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Amir Lerman, C. Michael Gibson

September 16, 2014

Presentation TCT 2014

Experimental Requirements and Device Validation: Critical Changes Impacting Transition to Human Testing

Presenter: Alexandre Abizaid, Elazer R. Edelman, Greg L. Kaluza

September 16, 2014

Presentation TCT 2014

Translational Research in Transition: Emerging Tools and Methods for Validation of Device Performance

Presenter: Alexandre Abizaid, Elazer R. Edelman, Dawn Bardot

September 16, 2014

News Conference News TCT 2014

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

September 13, 2014

News Conference News TCT 2013

Regulatory Hurdles Pose Challenges for Device Approvals in US, Europe

October 30, 2013

News Conference News TCT 2013

Memories of TCT from the Beginning: Martin B. Leon, MD

October 29, 2013

Presentation TCT 2013

Neurological complications following PCI - incidence and trends during a period of transition from femoral to radial access. Observational data from the British Cardiovascular...

Presenter: Karim Ratib, Mamas Mamas, Adrian Large, Samer Arnous, Helen Routledge, Peter Ludman, Doug Fraser, Jim Nolan

January 31, 2013

Presentation TCT 2012

Building a Niche: How to Transition from the "New" Interventionalist to the "Expert"

Presenter: James Zidar

October 26, 2012

News Conference News TCT 2012

Flexibility with Future Reform, Contract Negotiations Key to Career Success

October 24, 2012

Presentation TCT 2012

TCT-32. Neurological Complications Following PCI - Incidence and Trends During a Period of Transition from Femoral to Radial Access. Observational Data from the British...

Presenter: Karim Ratib

October 23, 2012

Presentation TCT 2012

The Mitochondrial Permeability Transition Pore is a Target for Pharmacological Cardioprotection in Human Hypertrophic Cardiomyopathy

Presenter: Paul S. Rees, Sean M. Davidson, Sian E. Harding, Perry M. Elliott, Derek J. Hausenloy, Derek M. Yellon

January 03, 2012

Advertisement

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Are Full, Formal Guidelines Still Useful in the Rapidly Changing TAVR Field?

TMVR Clinical Trial Design: Early Insights from Industry

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

FDA Perspectives

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Cangrelor IV: Transitioning to Oral ADP Antagonists

Keynote: Simplified Trials, Community Engagement Key to Reinvention of Clinical Research

Discussion Highlights Merits, Limitations of Small Trials

Bendavia to Prevent Mitochondrial Transition Pore Opening

Experimental Requirements and Device Validation: Critical Changes Impacting Transition to Human Testing

Translational Research in Transition: Emerging Tools and Methods for Validation of Device Performance

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

Regulatory Hurdles Pose Challenges for Device Approvals in US, Europe

Memories of TCT from the Beginning: Martin B. Leon, MD

Neurological complications following PCI - incidence and trends during a period of transition from femoral to radial access. Observational data from the British Cardiovascular...

Building a Niche: How to Transition from the "New" Interventionalist to the "Expert"

Flexibility with Future Reform, Contract Negotiations Key to Career Success

TCT-32. Neurological Complications Following PCI - Incidence and Trends During a Period of Transition from Femoral to Radial Access. Observational Data from the British...

The Mitochondrial Permeability Transition Pore is a Target for Pharmacological Cardioprotection in Human Hypertrophic Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content